HC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $27
Immix Biopharma Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
Immix Biopharma Q3 EPS $(0.19), Inline
Immix Biopharma’s NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026
Immix Biopharma To Present An NXC-201 Abstract At American Society Of Hematology Annual Meeting, December 12-15
Immix Biopharma (IMMX) Stock Sees Modest Fair Value Lift After Split Analyst Revisions
Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
Immix Biopharma, Inc. (IMMX) Shareholder/Analyst Call Transcript
Immix Biopharma Reports 89% Complete Response Rate in Phase 2 NXC-201 Trial
Needham Maintains Buy on Immix Biopharma, Raises Price Target to $30
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis
Mizuho Maintains Outperform on Immix Biopharma, Raises Price Target to $26
Morgan Stanley Maintains Overweight on Immix Biopharma, Lowers Price Target to $19
HC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $25
Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Needham Initiates Coverage On Immix Biopharma with Buy Rating, Announces Price Target of $21
All You Need to Know About Immix Biopharma (IMMX) Rating Upgrade to Buy
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.